News >

Expert Provides Clarity on Treatment of Advanced HCC

Angelica Welch
Published: Thursday, Jun 28, 2018

Mitesh J. Borad, MD

Mitesh J. Borad, MD

Although hepatocellular carcinoma is less frequent in the United States with less than 40,000 cases per year, the global incidence per year is estimated to be 782,000 cases, said Mitesh J. Borad, MD.

Borad says that patients can be broadly categorized into 3 stages: early-, intermediate-, and advanced-stage disease. In early-stage disease, surgery or transplant is a viable option, and in intermediate- and advanced-stage disease, locoregional therapy or systemic therapy should be considered.

Liver-Directed Therapies

Liver-directed therapies include embolization, radiofrequency ablation, cryoablation, radioembolization, alcohol ablation, and external beam radiation.

Borad said that the take-home message from these 2 studies is that Y-90 remains a reasonable modality to treat HCC, despite the negative studies. Future studies should focus on liver-limited cases and earlier-stage disease to potentially optimize the use of Y-90.

Systemic Therapy

In the first-line setting, patients with advanced HCC should be treated systemically with either sorafenib or lenvatinib (Lenvima), Borad says.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x